Today: 27 June 2026
Reckitt Benckiser share price slips in early London trade as special dividend reset stays in focus
6 February 2026
1 min read

Reckitt Benckiser share price slips in early London trade as special dividend reset stays in focus

London, Feb 6, 2026, 09:17 GMT — Regular session

  • Reckitt Benckiser shares fell about 0.7% in early trade, tracking a softer UK market.
  • The stock is still adjusting after a 235p special dividend and a 24-for-25 share consolidation that took effect this week.
  • Investors are looking to the company’s Feb. 19 CAGNY presentation for fresh clues on the post-divestment plan.

Shares in Reckitt Benckiser Group plc fell 0.7% to 6,368 pence in early London trading on Friday, after closing at 6,414 pence in the prior session. The stock has traded between 4,585.8 pence and 6,434 pence over the past year.

The move matters because the stock is still settling after a large, one-off return of capital that can distort day-to-day moves and confuse comparisons. On Jan. 7, the company set out plans for a 235 pence-per-share special dividend — about £1.6 billion in total — alongside a 24-for-25 share consolidation, meaning holders received fewer shares with a higher price per share to keep overall value broadly similar.

Reckitt said the share consolidation became effective on Feb. 2 and updated its share capital and voting rights for UK disclosure rules. The company reported 674,005,752 ordinary shares in issue, with 29,252,346 held in treasury, leaving total voting rights of 644,753,406.

The stock had risen in the prior two sessions before Friday’s dip. Reckitt gained 2.23% on Feb. 5 and 2.40% on Feb. 4, based on historical pricing data, as investors repositioned after the corporate action.

Cash returns have also run alongside buybacks. Reckitt confirmed on Feb. 2 it had completed the second tranche of its £1 billion share buyback programme, purchasing 3,461,470 shares at an average price of £59.46 between Oct. 22 and Jan. 28, and holding those shares in treasury.

The broader tone in London was not helping. The FTSE 100 was down about 0.3% in early trade.

Reckitt has framed the capital return as part of a broader reshaping after selling its Essential Home business. In a Dec. 31 statement on completing that divestment to Advent International, Chief Executive Kris Licht called it “a major step forward in our strategy.” reckitt.com

Investors now want detail on what the new Reckitt looks like, not just how much cash it sends back. The company said Licht and Chief Financial Officer Shannon Eisenhardt will present at the Consumer Analyst Group of New York conference on Feb. 19, with a webcast scheduled for 15:00-15:45 GMT.

The next near-term mechanical catalyst is the dividend itself. Data published by Hargreaves Lansdown shows the special dividend is due to be paid on Feb. 20, after the stock went ex-dividend on Feb. 2 — meaning new buyers after that date are not entitled to the payout.

But the trade can still go wrong for holders who treat the dividend as “free money.” A special dividend is a cash-out, not a fix for pricing pressure, slower volumes or a tough consumer backdrop, and the stock can stay choppy as funds rebalance around the corporate action and sector flows.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Wait 90 Days Before Buying More SpaceX Stock Due to Upcoming Share Unlocks
    June 27, 2026, 12:00 PM EDT. Space Exploration Technologies (SpaceX) recently made a record-breaking $75 billion initial public offering (IPO), valuing the company at $1.77 trillion. Although its stock briefly surged, it has dropped 3% since debut. Investors should consider waiting 90 days before buying more shares due to an upcoming lockup period, during which insiders are restricted from selling. After this period, additional shares will enter the market, potentially pressuring the stock price downward. SpaceX only floated about 4% of shares initially, with gradual increases expected over time. Historically, blockbuster IPOs often underperform in their first years, so patience and reassessment after the lockup expiration in September is advised to gauge true market response and valuation.

Latest articles

PayPal stock surge shifts short-interest story into next week

PayPal stock surge shifts short-interest story into next week

27 June 2026
PayPal surged 4.5% to $44.29 Friday on trading volume more than double its 65-day average, following a 9.7% jump in short interest to 54.35 million shares as of June 15, equal to 6.2% of float; despite the rally, shares remain 44% below last year’s high, with the stock still seen as a turnaround play and a shortened trading week ahead due to the July 3 U.S. holiday.
Uber (NYSE:UBER) grabs $4.9 billion run as safety, robotaxis in focus

Uber (NYSE:UBER) grabs $4.9 billion run as safety, robotaxis in focus

27 June 2026
Uber surged 5.47% to $76.20 on Friday with trading volume 3.46 times its 65-day average, as investors weighed tighter U.S. driver background checks set to remove tens of thousands of gig workers starting Monday—raising potential impacts on trips, wait times, and margins while the stock remains 25.3% below its 52-week high.
Honeywell (NASDAQ:HON) heads into split week with $464 level on traders’ radar

Honeywell (NASDAQ:HON) heads into split week with $464 level on traders’ radar

27 June 2026
Honeywell’s two-for-one split launches Monday, giving investors one Honeywell Technologies share and one Honeywell Aerospace (HONA) share for every two old shares, with the combined package valued at $464.42 at Friday’s close; both stocks debut as separate S&P 500 members, while HONA joins the S&P 100, setting up a pivotal test for holders as the market reopens.
Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
NIO stock jumps after profit alert flags first quarterly operating profit — what investors watch next
Previous Story

NIO stock jumps after profit alert flags first quarterly operating profit — what investors watch next

Ford stock slips before market open as EV sales dive and Geely talks linger
Next Story

Ford stock slips before market open as EV sales dive and Geely talks linger

Go toTop